Please assess the completion status of the following clinical trial:

Trial Title: First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 y.o.~* Claudication in Rutherford Class 1-5,~* Lesion in the femoropopliteal artery defined as \>50% and \< 99% diameter stenosis with length of up to 10 cm in vessel diameter of 3-7 mm~* Chronic total occlusions of length less than 100 mm~* Ability to cross the lesions with a guidewire.~Exclusion Criteria:~* Critical acute or chronic limb ischemia~* Acute coronary syndrome~* Chronic kidney disease stage III-V~* Restenotic lesion~* Femoropopliteal graft~* Known allergy to clopidogrel or aspirin~* History of stroke within past 6 months~* Age \> 80 y.o.~* Life expectancy \< 2 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Plain Balloon Angioplasty (Type: ACTIVE_COMPARATOR): Plain Balloon Angioplasty
- microcrystalline Paclitaxel Coated Balloon (PAK) (Type: EXPERIMENTAL): plain balloon angioplasty followed by mcPCB dilation

Based on this trial design, predict the completion outcome and termination type (if applicable).